PMA device
NOVOTTF-100A System
Novocure, GmbH · Stimulator, Low Electric Field, Tumor Treatment (NZK, Class III) · First FDA decision Aug 8, 2013, newest Aug 8, 2013Brain tumors
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
46
Naming "NOVOTTF-100A"
MAUDE reports
0
Brand "NOVOTTF-100A", since 2015
PubMed studies
24
Mentioning "NOVOTTF-100A"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NOVOTTF-100A System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- NOVOTTF-100A SYSTEMPMA supplement
P100034-S004 · Decided Aug 8, 2013 · 122 days after receipt · Normal 180 Day Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Tumor Treatment Field Therapy (TTFT)Local determinationIn effectL34823CGS Administrators, LLCUpdated Feb 21, 2020
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Positron Emission Tomography for Initial Treatment Strategy in Solid Tumors and MyelomaNational analysisReview closedCAG-00181R3Updated Sep 21, 2026
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Treatment of Motor Function Disorders with Electric Nerve StimulationNational determinationOn the books160.2Updated Aug 17, 2023
- Blood Brain Barrier Osmotic Disruption for Treatment of Brain TumorsNational determinationOn the books110.20Updated Mar 17, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "NOVOTTF-100A", any status and sponsor, newest update first.
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT04396860 · 159 participants · Start Sep 1, 2020 · Primary completion Jan 13, 2023
Device: NovoTTF-100A Device · For: Gliosarcoma; MGMT-Unmethylated Glioblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 285 sites in all
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaPivotal-lookingActive, not recruiting
NovoCure GmbHNot on our public-company list
NCT06556563 · 741 participants (planned) · Start Feb 3, 2025 · Primary completion Apr 2029
Device: Optune® device · For: Glioblastoma
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 102 sites in all
Emory UniversityAcademic, hospital or other
NCT05310448 · 10 participants (planned) · Start May 11, 2022 · Primary completion Sep 1, 2027
Device: Optune device · For: Glioma
Sites: Atlanta, Georgia · 3 sites in all
43 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NOVOTTF-100A", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NZK
813 reports: 1 malfunction, 806 injury, 6 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NOVOTTF-100A"[tiab]. The summary above synthesizes these.
- NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R, Wong ET, Kanner AA, et al. · Eur J Cancer · 2012Clinical Trial, Phase III, Comparative Study
- Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.
Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, et al. · Cancers (Basel) · 2019Review
- NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
Fonkem E, Wong ET · Expert Rev Neurother · 2012Research Support, Non-U.S. Gov't, Review
- Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.
Wong ET, Lok E, Swanson KD, et al. · Cancer Med · 2014Research Support, Non-U.S. Gov't
- Clinical practice experience with NovoTTF-100Aࡊ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM, Engelhard HH, Dinh Tran D, et al. · Semin Oncol · 2014
- Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET, Lok E, Swanson KD · Cancer Med · 2015Research Support, Non-U.S. Gov't
- Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100Aࡊ system versus best physician's choice chemotherapy.
Kanner AA, Wong ET, Villano JL, et al. · Semin Oncol · 2014Clinical Trial, Phase III, Comparative Study
- NovoTTFࡊ-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTALࡊ system user study.
Chaudhry A, Benson L, Varshaver M, et al. · World J Surg Oncol · 2015
- Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S, Klinger NV, Michelhaugh SK, et al. · J Neurosurg · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses.
Schettini F, Pineda E, Rocca A, et al. · Oncologist · 2025Network Meta-Analysis, Systematic Review
- Delayed response and survival from NovoTTF-100A in recurrent GBM.
Villano JL, Williams LE, Watson KS, et al. · Med Oncol · 2013Case Reports, Research Support, Non-U.S. Gov't
- Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Lacouture ME, Davis ME, Elzinga G, et al. · Semin Oncol · 2014
Other devices of this type
Also filed under product code NZK.
- OptuneNovocure, GmbH · PMA 2024
- Optune GioNovocure, GmbH · PMA 2026
- Novocure GmbHs Optune GioNovocure, GmbH · PMA 2026
- Optune Gio - Maxpoint Version 2.0Novocure, GmbH · PMA 2025
- Novocure's Optune SystemNovocure, GmbH · PMA 2016
- NOVOTFF-100A SystemNovocure, GmbH · PMA 2014
- Novo TTF-100A SystemNovocure, GmbH · PMA 2014
- Novocure NOVOTTF-100A SystemNovocure, GmbH · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.